Method validation
A second notable update is the clearer articulation of method suitability in the presence of product. The chapter now explicitly states that the ability of the method to detect Bcc in the tested product must be established and that this suitability should be reconfirmed whenever there is a change in testing performance or a change in the product that could affect the outcome. It also states that the incubation time used during method suitability should not exceed the shortest incubation period specified for the method. This is a subtle but important point. It prevents laboratories from compensating for poor recovery by extending incubation beyond the validated method window. Instead requires them to demonstrate genuine recovery capability under realistic test conditions. From a quality systems perspective, this reflects a stronger expectation that the test must be robust in the real product matrix, not just theoretically effective.
Another meaningful update is the formal addition of the ‘Recommended Culture Media’ section. USP now gives explicit compositions for stock buffer solution, phosphate buffer solution pH 7.2, buffered sodium chloride–peptone solution pH 7.0, soybean–casein digest broth and BCSA. The chapter clearly notes that this section is informational and that alternative media may still be used provided their suitability can be demonstrated. This is a pragmatic change. Rather than forcing every laboratory to use a single rigid formulation, USP provides a well-defined reference point that supports standardisation while still permitting scientifically justified alternatives. For contract laboratories, multi-site manufacturers and firms managing method transfer, such compendial transparency is especially useful because it reduces ambiguity about expected baseline formulations and preparation conditions.
Test interpretation
The chapter also sharpens the interpretation and confirmation of suspect isolates. On BCSA, possible Bcc presence is indicated by greenish-brown colonies with yellow halos or white colonies surrounded by a pink-red zone. However, USP makes clear that any growth on BCSA must be confirmed by identification testing, with a specific cross-reference to Chapter〈1113〉 Microbial Characterization, Identification and Strain Typing for additional information. This is a worthwhile update because colonial morphology alone is not sufficiently specific for final disposition decisions. By hardwiring confirmatory identification into the chapter, USP reduces the risk of false-positive conclusions and improves the defensibility of laboratory decisions during regulatory review.
Background to the updates
Why has USP made these updates? The answer appears to be less about changing the principle of Bcc testing and more about improving consistency, reproducibility and fitness for purpose. The chapter already had a defined purpose, but earlier ambiguity around media composition, suitability expectations and interpretation could lead to variable practice between laboratories. The revised text brings greater precision to routine implementation. It also reflects the broader regulatory movement toward performance-based microbiology, where the key question is whether the laboratory can demonstrate that the method works reliably for its own product and process context. In other words, the update supports a risk-based quality mindset - use the compendial method, but prove that it is suitable, selective and scientifically controlled in your hands.
There is also a practical signal in the chapter’s continued insistence on low-level challenge inocula, specifically not more than 100 cfu for growth promotion and suitability testing. This matters because an over-challenged method may appear effective even though it performs poorly near the limit of detection. By retaining and emphasising this low inoculum expectation, USP ensures the method is assessed closer to routine reality, where low-level contamination is often the genuine concern. It also strengthens comparability across laboratories because the challenge level is constrained rather than loosely defined.
For practicing microbiologists, the application of the revised chapter is straightforward but important. Firstly, laboratories should review their media qualification protocols to ensure they explicitly address growth promotion, inhibition and indication. Secondly, method suitability studies should be revisited, particularly for products with antimicrobial properties, surfactants, preservatives or unusual physical characteristics. USP explicitly notes that any antimicrobial activity requires modification of the procedure, with reference to neutralisation or removal approaches described in Chapter 〈61〉. Thirdly, laboratories should verify that suspect colonies recovered on BCSA are routed through a validated identification workflow rather than being interpreted morphologically alone. Finally, any local preparation of media should be checked against the newly stated informational formulations and preparation parameters.
